Protagonist Therapeutics (PTGX) Stock Overview
Operates as a discovery and development company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PTGX Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Protagonist Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$105.40 |
| 52 Week High | US$105.99 |
| 52 Week Low | US$39.60 |
| Beta | 2.24 |
| 1 Month Change | 14.47% |
| 3 Month Change | 20.68% |
| 1 Year Change | 124.83% |
| 3 Year Change | 389.10% |
| 5 Year Change | 307.42% |
| Change since IPO | 800.85% |
Recent News & Updates
Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide
Jan 30Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues
Oct 11
Recent updates
Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide
Jan 30Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues
Oct 11Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27%
Jun 13Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
Mar 11Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck
Jan 13The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey
Oct 16Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25Protagonist: Too Many Red Flags
Jun 08Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Shareholder Returns
| PTGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.0% | 3.2% | -0.6% |
| 1Y | 124.8% | 31.7% | 16.0% |
Return vs Industry: PTGX exceeded the US Biotechs industry which returned 25.8% over the past year.
Return vs Market: PTGX exceeded the US Market which returned 14% over the past year.
Price Volatility
| PTGX volatility | |
|---|---|
| PTGX Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: PTGX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PTGX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 132 | Dinesh Patel | www.protagonist-inc.com |
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity.
Protagonist Therapeutics, Inc. Fundamentals Summary
| PTGX fundamental statistics | |
|---|---|
| Market cap | US$6.37b |
| Earnings (TTM) | -US$130.15m |
| Revenue (TTM) | US$46.02m |
Is PTGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTGX income statement (TTM) | |
|---|---|
| Revenue | US$46.02m |
| Cost of Revenue | US$0 |
| Gross Profit | US$46.02m |
| Other Expenses | US$176.17m |
| Earnings | -US$130.15m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04 |
| Gross Margin | 100.00% |
| Net Profit Margin | -282.83% |
| Debt/Equity Ratio | 0% |
How did PTGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/31 10:24 |
| End of Day Share Price | 2026/03/31 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Protagonist Therapeutics, Inc. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |
| Timothy Chiang | Capital One Securities, Inc. |